← All stories
Markets
AstraZeneca and Amgen's Tezspire Achieves All Primary and Secondary Endpoints in Phase III CROSSING Trial for Eosinophilic Esophagitis
On 27 August 2026, AstraZeneca (LSE/STO/NYSE: AZN) announced that Tezspire (tezepelumab), co-developed with Amgen, delivered statistically significant and clinically meaningful improvements across both co-primary and all key secondary endpo…
Covered by 1 outlet
All coverage · 1 article